IP Library Granted Patent US 9,676,852
Granted Patent B2
US 9,676,852 · App. 15/165,152 · Granted Jun 13, 2017

Antibodies directed against ICOS and uses thereof

Inventors: Julien Faget (Lyons, FR); Christophe Caux (Lyons, FR); Christine Menetrier-Caux (Lyons, FR); Jacques Nunes (Marseilles, FR); Daniel Olive (Marseilles, FR)
Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; UNIVERSITE D'AIX-MARSEILLE; Universite Claude Bernard—Lyon 1; Centre Leon Berard
C07K16/28C07K16/2818G01N33/56972G01N33/57415A61K2039/505C07K2317/565C07K2317/75C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,676,852
App. No.
15/165,152
Granted
Jun 13, 2017
Kind
B2
Abstract

The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Claims (42)

1. A method of treatment of cancer in a patient in need thereof, the method comprising administering to the patient an antibody directed against human Inducible T-cell costimulator (ICOS), wherein said antibody competes for binding to human ICOS with an antibody having the following 6 CDRs:

(SEQ ID NO: 7, H-CDR1)

GYTFTTYWMH;

(SEQ ID NO: 8, H-CDR2)

EIDPSDSYVNYNQNFKG;

(SEQ ID NO: 9, H-CDR3)

FDY;

(SEQ ID NO: 10, L-CDR1)

RSSKSPLHSNGNIYLY;

(SEQ ID NO: 11, L-CDR2)

RMSNLAS;

(SEQ ID NO: 12, L-CDR3)

MQHLEYPYT.

2. The method of treatment according to claim 1 , wherein the nucleotide sequences encoding the 6 CDRs are:

(SEQ ID NO: 1, H-CDR1)

GGCTACACCTTCACCACCTACTGGATGCAC;

(SEQ ID NO: 2, H-CDR2)

GAGATTGATCCTTCTGATAGTTATGTTAACTACAATCAAAACTTTAAGGG

C;

(SEQ ID NO: 3, H-CDR3)

TTTGATTAC;

(SEQ ID NO: 4, L-CDR1)

AGGTCTAGTAAGAGTCCCCTGCATAGTAACGGCAACATTTACTTATAT;

(SEQ ID NO: 5, L-CDR2)

CGGATGTCCAACCTTGCCTCA;

(SEQ ID NO: 6, L-CDR3)

ATGCAACATCTAGAATATCCGTACACG.

3. The method of treatment according to claim 1 , wherein said cancer is human malignant lymphoma.

4. The method of treatment according to claim 1 , wherein said cancer is ovarian cancer.

5. The method of treatment according to claim 1 , wherein said cancer is cervical cancer.

6. The method of treatment according to claim 1 , wherein said cancer is breast cancer.

7. The method of treatment according to claim 1 , wherein said cancer is colon cancer.

8. The method of treatment according to claim 1 , wherein said cancer is lung cancer.

9. The method of treatment according to claim 1 , wherein said cancer is prostate cancer.

10. The method of treatment according to claim 1 , wherein said cancer is head and neck cancer.

11. The method of treatment according to claim 1 , wherein said cancer is pancreatic cancer.

12. The method of treatment according to claim 1 , wherein said cancer is bladder cancer.

13. The method of treatment according to claim 1 , wherein said cancer is colorectal cancer.

14. The method of treatment according to claim 1 , wherein said cancer is kidney cancer.

15. The method of treatment according to claim 1 , wherein said cancer is stomach cancer.

16. The method of treatment according to claim 1 , wherein said cancer is skin cancer.

17. The method of treatment according to claim 1 , wherein said cancer is esophageal cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2016
From: FAGET, JULIEN; CAUX, CHRISTOPHE; MENETRIER-CAUX, CHRISTINE; NUNES, JACQUES; OLIVE, DANIEL
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT JEAN PAOLI & IRENE CALMETTES; UNIVERSITE D'AIX MARSEILLE; UNIVERSITE CLAUDE BERNARD - LYON 1; CENTRE LEON BERARD
Reel/Frame 039568/0578 →
Priority Claims (1)
EP 11305380 · Mar 31, 2011 · regional
Continuity (2)
Division 14008423
Related Publication 20160264666A1 · Sep 15, 2016